GENEVA--(BUSINESS WIRE)--Sept. 21, 2006--Bioenvision, Inc. (NasdaqGM:BIVN) today announced the latest results from the ongoing European study (BIOV-111) of Evoltra(R) (clofarabine) in pediatric acute lymphoblastic leukemia (ALL) - presented for the first time this week - have confirmed Bioenvision’s recently approved drug, Evoltra(R), delivers a significant response rate in a difficult to treat patient population. In addition, updated results from the pivotal clinical study CLO-212* showed that response to clofarabine provides the opportunity for patients to proceed to stem cell transplant, which offers them the best chance for long term survival.
